The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.
NeXT Personal identifies circulating tumor DNA in 81% of early-stage lung adenocarcinoma cases, offering potential for better disease stratification and outcome prediction. Study: Ultrasensitive ctDNA ...
InvestorsHub on MSN
BioAffinity launches large-scale clinical study for lung cancer detection technology
Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results